NORML today hand-delivered over 10,000 written comments from US citizens calling on federal and international agencies to amend the international prohibition of cannabis. The public comments, which were requested earlier this month by the US Food and Drug Administration, will be considered as part of the World Health Organization’s ongoing review of the plant’s international classification.
Under international treaties, the marijuana plant is classified in the most restrictive schedules available for controlled substances. NORML maintains that this scheduling does not accurately reflect the plant’s widespread therapeutic acceptance and relatively low abuse potential.
The United National’s international prohibition of cannabis is a relic from a bygone era. This decision, which was largely a political one made over 50 years ago, does not accurately reflect either the available science or the rapidly changing political and cultural status of cannabis worldwide.
Members of NORML’s Board of Directors also submitted their own written testimony to the FDA, opining: “In general, the safety, dependence, and usage profile of cannabis compares favorably to alcohol, tobacco, and other unscheduled substances. For this reason, NORML believes that cannabis [ultimately] should be withdrawn from the treaty framework entirely.”
As of 1pm EST on April 23rd, there are only 6,566 comments submitted through the federal site. With the comments by NORML members, we will have submitted 61% of all public comments should that number hold.
Background per Regulations.gov:
The United States is a party to the 1971 Convention on Psychotropic Substances (Psychotropic Convention). Article 2 of the Psychotropic Convention provides that if a party to the convention or WHO has information about a substance, which in its opinion may require international control or change in such control, it shall so notify the Secretary-General of the United Nations (the U.N. Secretary-General) and provide the U.N. Secretary-General with information in support of its opinion.
Paragraph (d)(2)(A) of the CSA (21 U.S.C. 811) (Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970) provides that when WHO notifies the United States under Article 2 of the Psychotropic Convention that it has information that may justify adding a drug or other substances to one of the schedules of the Psychotropic Convention, transferring a drug or substance from one schedule to another, or deleting it from the schedules, the Secretary of State must transmit the notice to the Secretary of Health and Human Services (Secretary of HHS). The Secretary of HHS must then publish the notice in the Federal Register and provide opportunity for interested persons to submit comments that will be considered by HHS in its preparation of the scientific and medical evaluations of the drug or substance.